(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

May 23, 2025 Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products ...

On the surface, macular degeneration treatment Eylea continued its juggernaut path in 2022. On Tuesday, when Bayer reported fourth quarter earnings, it showed 3.2 billion euros ($3.4 billion ...

Bayer has licensed exclusive marketing rights outside the United States, where the companies share equal profits from the sales of Eylea. Eylea’s intravitreal injection 40 mg/mL has been approved for ...

Increased ocular pressure (5%) was the only ocular treatment-emergent ... developed by Regeneron and Bayer AG. Regeneron maintains exclusive rights to EYLEA and EYLEA HD in the U.S. Bayer has ...